The rising incidence of coronary artery diseases, cardiac ailments, and neurodegenerative and infectious diseases has led to the demand for antisense and RNai therapeutics. The market exhibits a strong pipeline of product and is looking forward to introduce several advancements in the RNAi drug delivery technology.
The potential commercialization of a few candidates under research and development will help the antisense and RNAi therapeutics market to pick up pace in North America in the near future.

The global Antisense and RNAi Therapeutics market was valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Antisense and RNAi Therapeutics volume and value at global level, regional level and company level. From a global perspective, this report represents overall Antisense and RNAi Therapeutics market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Antisense and RNAi Therapeutics in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their Antisense and RNAi Therapeutics manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

The following manufacturers are covered:
Tekmira Pharmaceuticals
Arbutus Biopharma
Alnylam Pharmaceuticals
Antisense Therapeutics
Silence Therapeutics
Isis Pharmaceuticals
Sirnaomics
Santaris
Roche

Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India

Segment by Type
RNA Interference
Antisense RNA

Segment by Application
Hospital
Clinic